SCHEMBL22726537

SCHEMBL22726537

COC(=O)c1c(OC)cc(B2OC(C)(C)C(C)(C)O2)cc1OC(F)F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 2/20 0.37
CSF1R P07333 1/20 0.33
POLB P06746 3/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
MAPK1 P28482 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MAPT P10636 2/20 0.32
LMNA P02545 2/20 0.32
NPC1 O15118 1/20 0.32
TP53 P04637 1/20 0.32
TSHR P16473 1/20 0.32
RAB9A P51151 1/20 0.32
DGAT1 O75907 1/20 0.32
STING1 Q86WV6 1/20 0.32
AAK1 Q2M2I8 1/20 0.31
HIF1A Q16665 1/20 0.31
GAA P10253 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22491269 0.89 CSF1R (0.38) NR1I2CSF1RPOLBDGAT1AAK1
SCHEMBL31312973 0.89 CA12 (0.36) NR1I2CSF1RMEN1KMT2AMAPK1
SCHEMBL22726542 0.88 AAK1 (0.37) NR1I2CSF1RDGAT1STING1AAK1
SCHEMBL22726979 0.86 POLB (0.33) NR1I2CSF1RPOLBMEN1KMT2A
SCHEMBL23162244 0.85 SIK1 (0.42) NR1I2CSF1RMAPK1SMN1; SMN2MAPT
SCHEMBL21591205 0.83 SIK1 (0.46) CSF1RMEN1KMT2ARAB9A
SCHEMBL23162299 0.82 CYP3A4 (0.40) NR1I2CSF1RPOLBDGAT1AAK1
SCHEMBL27452322 0.81 CSF1R (0.37) NR1I2CSF1RPOLBMEN1KMT2A
SCHEMBL29793578 0.81 SIK1 (0.36) CSF1RMAPK1SMN1; SMN2NPC1TP53
SCHEMBL20564345 0.81 HIF1A (0.38) CSF1RKMT2AMAPK1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12391679-B2 Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases ONCO3R THERAPEUTICS BV (BE) 2025-08-19 US disclosed
EP-3976189-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2024-07-03 EP disclosed
EP-3976189-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2024-07-03 EP disclosed
US-20220340548-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2022-10-27 US disclosed
WO-2020239658-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2020-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340548-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES IL1B, IL1A, IL36G NR1I2 1614/4885CSF1R 288/4885POLB 387/4885
US-12391679-B2 Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases IL5, IL15, IL1A NR1I2 1575/4885CSF1R 290/4885POLB 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.